Inhibrx Biosciences Advances HexAgon-HN Study for Head, Neck Cancer

Inhibrx Biosciences Inc. (NASDAQ:INBX) is one of the most profitable new stocks to buy now. On July 18, it was reported that Inhibrx Biosciences is currently conducting a pivotal Phase 2/3, randomized clinical study, titled “HexAgon-HN,” to evaluate the efficacy and safety of INBRX-106.

The study combines INBRX-106, which is a hexavalent OX40 agonist antibody, with pembrolizumab (an anti-PD-1 antibody) as a first-line treatment for patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma/HNSCC that expresses PD-L1 (with a Combined Positive Score of ≥20). The combination therapy is being compared against pembrolizumab monotherapy. Both INBRX-106 and pembrolizumab are administered intravenously every 3 weeks.

The study design is randomized with a parallel assignment model, and the Phase 3 portion will be double-blind, ensuring that neither participants nor investigators are aware of the treatment allocations. The primary objective is to evaluate treatment efficacy. The HexAgon-HN study commenced on May 14 earlier this year and is actively recruiting participants. The most recent update regarding the study’s progress was submitted on July 15.

Inhibrx Biosciences Inc. (NASDAQ:INBX) is a clinical-stage biopharmaceutical company that engages in the development of biologic therapeutics for people with life-threatening conditions.

While we acknowledge the potential of INBX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.